{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:05:30Z","timestamp":1783105530138,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune checkpoint inhibition with anti-PD(L)1 and anti-CTLA4 antibodies has significantly changed cancer treatment during the last 10\u00a0years. Nevertheless, boosting the immune system with immune checkpoint inhibition can result in immune-related adverse events, affecting different organ systems, among which the endocrine system is the most affected. However, there are few descriptions of the association of immune-related adverse events, and the pathophysiology of some is still lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case summary<\/jats:title>\n                <jats:p>Here, we report a 70-year-old Caucasian patient treated with nivolumab (anti-PD1 monoclonal antibody) after resection of a unique relapse of melanoma in the neck region who presented with sicca syndrome, extreme fatigue, and weight loss 6\u00a0months after the start of anti-PD1 therapy. Blood tests revealed hypoglycemia and secondary hypocortisolism due to isolated adrenocorticotrophic hormone deficiency. Interestingly, brain methionine positron emission tomography\/magnetic resonance revealed physiological metabolism of the pituitary gland, which was not increased in size, and no hypophyseal metastasis was detected. The sicca syndrome investigation revealed the absence of anti-SSA\/SSB antibodies, while the labial salivary gland biopsy showed lymphoplasmatocytic infiltrates with a focus score of 1. To provide new insights into the physiopathology of the anti-PD1-related sialadenitis, we investigated the distribution of aquaporins 5 by immunostaining on the labial salivary gland acini, and compared this distribution with the one expressed in the primary Sj\u00f6gren\u2019s syndrome. Contrary to patients with primary Sj\u00f6gren\u2019s syndrome (in whom aquaporins 5 is mainly expressed at the basolateral side), but similar to the patients with no sialadenitis, we observed expression of aquaporins 5 at the apical pole. This new finding deserves to be confirmed in other patients with anti-PD1-related sialadenitis. Owing to these immune-related adverse events, anti-PD1 was stopped; nevertheless, the patient developed a new relapse 1\u00a0year later (March 2020) in the neck region, which was treated by radiotherapy. Since then, no relapse of melanoma was seen (1.5\u00a0years after radiotherapy), but the patient still requires hypophyseal replacement therapy. The sialoadenitis resolved partially.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We report a combination of sialoadenitis and hypophysitis explaining extreme fatigue in a patient who was treated in the adjuvant setting with anti-PD1 for a melanoma relapse.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03663-6","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T01:02:27Z","timestamp":1670547747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-566X","authenticated-orcid":false,"given":"Sylvain Raoul","family":"Simeni Njonnou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-9161","authenticated-orcid":false,"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-3351","authenticated-orcid":false,"given":"Marie-Josiane","family":"Ntsama Essomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-8739","authenticated-orcid":false,"given":"Marie-Lucie","family":"Racu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-5049","authenticated-orcid":false,"given":"Fernando","family":"Kemta Lekpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1388-9262","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Vandergheynst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"5256","key":"3663_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"7","key":"3663_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","volume":"20","author":"GK Pennock","year":"2015","unstructured":"Pennock GK, Chow LQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812\u201322.","journal-title":"Oncologist"},{"issue":"1","key":"3663_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.annpat.2016.12.016","volume":"37","author":"M Duruisseaux","year":"2017","unstructured":"Duruisseaux M, Lize-Dufranc C, Badoual C, Bibeau F. Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment. Ann Pathol. 2017;37(1):46\u201354.","journal-title":"Ann Pathol"},{"key":"3663_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jgo.2019.05.013","volume":"11","author":"L Kasherman","year":"2019","unstructured":"Kasherman L, Siu DHW, Lee KWC, Lord S, Marschner I, Lewis CR, et\u00a0al. Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis. J Geriatr Oncol. 2019;11:508\u201314.","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"3663_CR5","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183(6):2541\u201350.","journal-title":"J Exp Med"},{"issue":"1","key":"3663_CR6","first-page":"39","volume":"49","author":"A Kosmaczewska","year":"2001","unstructured":"Kosmaczewska A, Ciszak L, Bo\u0107ko D, Frydecka I. Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch Immunol Ther Exp (Warsz). 2001;49(1):39\u201346.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"3663_CR7","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75\u201397.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"3663_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et\u00a0al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374.","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"3663_CR9","doi-asserted-by":"publisher","first-page":"S480","DOI":"10.21037\/jtd.2018.01.111","volume":"10","author":"A Winer","year":"2018","unstructured":"Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018;10(Suppl 3):S480.","journal-title":"J Thorac Dis"},{"issue":"2","key":"3663_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"12","key":"3663_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et\u00a0al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375\u201391.","journal-title":"Ann Oncol"},{"key":"3663_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel S, Champiat S, Mateus C, Marabelle A, Michot J-M, Robert C, et\u00a0al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34\u201344.","journal-title":"Eur J Cancer"},{"key":"3663_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, et\u00a0al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70\u20136.","journal-title":"Cancer Treat Rev"},{"issue":"03","key":"3663_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(03):145\u201356.","journal-title":"Horm Metab Res"},{"issue":"3","key":"3663_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","volume":"58","author":"L Brilli","year":"2017","unstructured":"Brilli L, Danielli R, Ciuoli C, Calabr\u00f2 L, Di Giacomo AM, Cerase A, et\u00a0al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017;58(3):535\u201341.","journal-title":"Endocrine"},{"issue":"3","key":"3663_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen J, Sullivan R, et\u00a0al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181(3):211\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"3663_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/1346-8138.13437","volume":"44","author":"M Ishikawa","year":"2017","unstructured":"Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2017;44(1):109\u201310.","journal-title":"J Dermatol"},{"issue":"4","key":"3663_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","volume":"57","author":"N Ohara","year":"2018","unstructured":"Ohara N, Ohashi K, Fujisaki T, Oda C, Ikeda Y, Yoneoka Y, et\u00a0al. Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review. Intern Med. 2018;57(4):527\u201335.","journal-title":"Intern Med"},{"issue":"10","key":"3663_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, et\u00a0al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63(10):905\u201312.","journal-title":"Endocr J"},{"issue":"5","key":"3663_CR20","doi-asserted-by":"publisher","first-page":"e00322","DOI":"10.1002\/rcr2.322","volume":"6","author":"S Takahashi","year":"2018","unstructured":"Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M. Nivolumab-induced sialadenitis: nivolumab-induced sialadenitis. Respirol Case Rep. 2018;6(5):e00322.","journal-title":"Respirol Case Rep"},{"issue":"1","key":"3663_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et\u00a0al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43\u201350.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, et\u00a0al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24:1259\u201369.","journal-title":"Oncologist"},{"key":"3663_CR23","first-page":"185","volume-title":"Aquaporins handbook of experimental pharmacology","author":"C Delporte","year":"2009","unstructured":"Delporte C. Aquaporins in secretory glands and their role in Sjogren\u2019s syndrome. In: Beitz E, editor. Aquaporins handbook of experimental pharmacology. Springer: Berlin; 2009. p. 185\u2013201."},{"issue":"11","key":"3663_CR24","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.3390\/ijms19113392","volume":"19","author":"M Soyfoo","year":"2018","unstructured":"Soyfoo M, Chivasso C, Perret J, Delporte C. Involvement of aquaporins in the pathogenesis, diagnosis and treatment of Sj\u00f6gren\u2019s syndrome. Int J Mol Sci. 2018;19(11):3392.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3663_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, et\u00a0al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019;11(4):225\u201336.","journal-title":"J Clin Med Res"},{"issue":"230","key":"3663_CR26","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45-230ra45.","journal-title":"Sci Transl Med"},{"issue":"7","key":"3663_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","volume":"21","author":"E Gonz\u00e1lez-Rodr\u00edguez","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21(7):804\u201316.","journal-title":"Oncologist"},{"issue":"9","key":"3663_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1507\/endocrj.EJ18-0147","volume":"65","author":"T Ach","year":"2018","unstructured":"Ach T, Yosra H, Jihen M, Abdelkarim Asma B, Maha K, Molka C, et\u00a0al. Cortisol cut-points for the glucagon stimulation test in the evaluation of hypothalamic pituitary adrenal axis. Endocr J. 2018;65(9):935\u201342.","journal-title":"Endocr J"},{"issue":"3","key":"3663_CR29","first-page":"114","volume":"37 Suppl 118","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals M, Maria A, Su\u00e1rez-Almazor ME, Lambotte O, Fisher BA, Hern\u00e1ndez-Molina G, et\u00a0al. Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol. 2019;37 Suppl 118(3):114\u201322.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3663_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard.2006.052647","volume":"66","author":"J Pijpe","year":"2007","unstructured":"Pijpe J, Kalk WWI, Bootsma H, Spijkervet FKL, Kallenberg CGM, Vissink A. Progression of salivary gland dysfunction in patients with Sjogren\u2019s syndrome. Ann Rheum Dis. 2007;66(1):107\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3663_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","volume":"181","author":"JMK de Filette","year":"2019","unstructured":"de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, et\u00a0al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019;181(3):363\u201374.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"3663_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.13424","volume":"200","author":"Z Quandt","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020;200(2):131\u201340.","journal-title":"Clin Exp Immunol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03663-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T01:02:37Z","timestamp":1670547757000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03663-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3663"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03663-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"18 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Administrative authorization and ethical approval were obtained from the ethical committee of the Erasmus Hospital. The reference number is P2022\/318.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Sandrine Aspeslagh has received fees for advisory boards for MSD, Rochem, Astra Zeneca, BMS, Sanofi and Pfizer over the last 36\u00a0months. There was no conflict of interest for the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}